Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain

18 Aug 2023

Abstract excerpt

MYD88 is the key signaling adaptor-protein for Toll-like and interleukin-1 receptors. A somatic L265P mutation within the Toll/interleukin-1 receptor (TIR) domain of MYD88 is found in 90% of Waldenström macroglobulinemia cases and in a significant subset of diffuse large B-cell lymphomas. MYD88-L265P strongly promotes NF-κB pathway activation, JAK-STAT signaling and lymphoma cell survival. Previous studies have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37591861
DOI: 10.1038/s41408-023-00896-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domainPMID 37591861Read ↗

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphomaSemantic proximity Read ↗

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.Semantic proximity Read ↗

Oncogenically active MYD88 mutations in human lymphoma.Semantic proximity Read ↗

MYD88 gene and protein: molecular architecture, signalling mechanisms and clinical implications in lymphoid malignancies.Semantic proximity Read ↗

[MyD88 L265P mutation and B cell tumor].Semantic proximity Read ↗

Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphomaSemantic proximity Read ↗

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.Semantic proximity Read ↗

Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.Semantic proximity Read ↗

Aggressive Lymphoplasmacytic Neoplasm With an Unusual In-frame Deletion of MYD88 Associated With TRAF3 and TP53 Mutations and Complex Karyotype.Semantic proximity Read ↗

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapySemantic proximity Read ↗

Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.Semantic proximity Read ↗

Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.